A minimális residualis betegség vizsgálatának jelentősége myeloma multiplex kezelése után
| Autor: | László Kereskai, Béla Kajtár, Gergely Papp, Márk Plander, János László Iványi, Zsuzsanna Szabó, Tamás Szendrei |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Oncology
medicine.medical_specialty business.industry Proportional hazards model Bortezomib General Medicine medicine.disease Minimal residual disease body regions Transplantation 03 medical and health sciences 0302 clinical medicine medicine.anatomical_structure hemic and lymphatic diseases Internal medicine medicine 030211 gastroenterology & hepatology Bone marrow Stage (cooking) business After treatment Multiple myeloma medicine.drug |
| Zdroj: | Orvosi Hetilap. 160:502-508 |
| ISSN: | 1788-6120 0030-6002 |
| DOI: | 10.1556/650.2019.31353 |
| Popis: | Abstract: Introduction: Prognostic impact of the detection of minimal residual disease (MRD) in multiple myeloma (MM) has been confirmed in numerous studies. Aim: Retrospective examination of our patient database (107 newly diagnosed multiple myelomas between 2007 and 2017). Flow cytometry (FCM) was performed as MRD assessment. Method: MRD assessment was performed in 56 patients (median age: 68 years), after induction treatment of multiple myeloma. The treatment contained bortezomib in 91%, autologous haematopoetic stem cell transplantation (ASCT) was perfomed in 50%. MRD detection was performed on bone marrow samples, predominantly in our hospital (BD FACScan, 3 colour, panel: CD38, CD138, CD19, CD45, CD56, CD28, CD117, cyKappa, cyLambda, 100 000 events). Statistical analysis: SPSS 13.0. Results: The progression-free survival (PFS) and the overall survival (OS) were significantly longer in MRD negative (n = 22) patients (PFS: 54 months, OS: 79% after 5 years) than MRD positive patients (n = 34, PFS: 22 months, OS 21% after 5 years, p = 0.001). Patients achieving complete response (CR) (n = 29) have different PFS (MRD negative CR: 60 months, MRD positive CR: 21 months, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|